TrianglePomalidomide after CAR T (NCT07532525)
Pomalidomide after CAR T trial for Recurrent B Acute Lymphoblastic Leukemia (NCT07532525). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for CD19-positive B-cell leukemia or lymphoma that has returned or not responded, in patients who have already received an approved CAR T therapy.
The idea: help the CAR T cells last. To work best, the cells must expand and persist in the blood. Pomalidomide, a pill that stimulates the immune system, may improve that. Patients start it four to eight weeks after their infusion and take it for ten doses.
This is a small pilot, about 12 patients, and the first question is safety. At the University of Michigan in Ann Arbor, Jennifer Agrusa leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.